Search the Newsreel

AirSculpt Sees Core Stabilization, Targets $100M-Plus GLP-1 Opportunity

AirSculpt Technologies (AIRS) is experiencing stabilization in its core body-contouring business after previous declines, attributing this to new talent and improved sales strategies. The company is also expanding into services for patients using GLP-1 weight-loss drugs, seeing a significant opportunity potentially exceeding $100 million …

AirSculpt® Partners with Tiger Aesthetics™ in First National Partnership to Offer alloClae™

AirSculpt®, a leader in minimally invasive body contouring, has announced its first national partnership with Tiger Aesthetics™ to offer alloClae™, an off-the-shelf structural adipose tissue. This collaboration aims to expand AirSculpt's body enhancement offerings, providing patients with a new treatment option for natural-looking volume …

Airsculpt Technologies(AIRS) Stock Options Chain | Quotes & News

This article provides access to the stock options chain, quotes, and news for Airsculpt Technologies (AIRS). It serves as a resource for investors looking for detailed financial information and market performance data for the company.

HC Wainwright Issues Pessimistic Outlook for CGEM Earnings

HC Wainwright Has Negative Estimate for Oculis Q3 Earnings

HC Wainwright has lowered its Q3 2026 EPS estimate for Oculis (NASDAQ: OCS) to a loss of $0.48 per share, maintaining a "Buy" rating and a $26 price target. Oculis previously reported a Q2 loss of $0.20 per share with $0.38 million in revenue …

AirSculpt Technologies (AIRS) shifts corporate headquarters from Miami Beach to Tampa

AirSculpt Technologies, Inc. (AIRS) has announced the relocation of its corporate headquarters from Miami Beach to Tampa, Florida, effective for corporate records and reporting purposes. This move was approved by the company's Board of Directors on August 5, 2026, and the new address will …

Hercules Capital (HTGC) Could Be 14% Below Fair Value As Earnings And Dividend Draw Focus

Dimensional Fund Advisors LP Purchases 227,982 Shares of 4D Molecular Therapeutics, Inc. $FDMT

Dimensional Fund Advisors LP has increased its stake in 4D Molecular Therapeutics (NASDAQ:FDMT) by 77.3%, purchasing an additional 227,982 shares to bring its total ownership to 522,823 shares, representing 1.0% of the company. Institutional investors now own 99.27% of the stock, while company insiders …

Amundi Sells 27,558 Shares of Cullen/Frost Bankers, Inc. $CFR

Amundi significantly reduced its stake in Cullen/Frost Bankers by selling 27,558 shares, retaining 2,956 shares valued at $405,000. Cullen/Frost Bankers reported strong quarterly earnings of $2.70 per share and revenue of $608.65 million, both exceeding analyst expectations. The company also declared a quarterly dividend …

Dimensional Fund Advisors LP Takes $5.49 Million Position in Ocular Therapeutix, Inc. $OCUL

Dimensional Fund Advisors LP has initiated a new position in Ocular Therapeutix, Inc. (NASDAQ:OCUL), purchasing 649,756 shares valued at approximately $5.49 million. This move is part of broader institutional interest, with hedge funds and other institutional investors collectively owning 59.21% of the biopharmaceutical company's …

Q2 Earnings Highs And Lows: LeMaitre (NASDAQ:LMAT) Vs The Rest Of The Surgical Equipment & Consumables - Specialty Stocks

Q2 Earnings Highs And Lows: LeMaitre (NASDAQ:LMAT) Vs The Rest Of The Surgical Equipment & Consumables - Specialty Stocks Let's dig into the relative performance of LeMaitre (NASDAQ:LMAT) and its peers as we unravel the now-completed Q2 surgical equipment & consumables - specialty earnings …

BERKLEY W R CORP Expands Stake in Agriculture & Natural Solutions Acquisition Corp (ANSC)

Can Clever Culture Systems (ASX:CC5) Fund Its Next Growth Phase?

Does AirSculpt (AIRS) Reaffirmed 2026 Revenue Guidance Offset Concerns From Softer Q2 Results?

AirSculpt Technologies (AIRS) reported softer Q2 2026 results with lower sales and a wider net loss, but reaffirmed its full-year 2026 revenue guidance at the lower end of its previously stated range. This commitment to guidance, despite recent performance, aims to stabilize investor concerns. …

Goldman Sachs Group (ANSC) discloses 4.3% holding in Agriculture & Natural Solutions

We Think Clever Culture Systems (ASX:CC5) Can Easily Afford To Drive Business Growth

AirSculpt at canaccord growth conference: turnaround gains traction

Hercules Resources Corp. Reports Earnings Results for the Third Quarter and Nine Months Ended June 30, 2026

Insight Molecular Diagnostics to Host Virtual KOL Event on

Insight Molecular Diagnostics Inc. (iMDx) will host a virtual KOL event on August 17, 2026, to discuss its GraftAssure platform and the potential for in-house heart transplant rejection testing. The event will feature Dr. Max Jacob Liebo, alongside iMDx's VP of Medical Affairs and …

Doctors to discuss in-house heart transplant testing Aug. 17

Insight Molecular Diagnostics (Nasdaq: IMDX) will host a virtual Key Opinion Leader (KOL) event on August 17, 2026, to discuss its GraftAssure dd-cfDNA platform. The event will feature cardiologist Max Jacob Liebo, MD, and iMDx executives, focusing on the GraftAssureDx kit for kidney and …

AirSculpt Technologies Shares Sink on Wider 2Q Loss, Outlook Cut

AirSculpt Technologies (AIRS) shares fell significantly after the company reported a wider-than-expected second-quarter loss and lowered its full-year outlook. The company's revenue guidance for 2024 was also reduced, leading to investor concern.

Cullinan Oncology stock hits 52-week high at 19.43 USD By Investing.com

Cullinan Oncology (CGEM) stock has reached a new 52-week high of $19.43, reflecting a substantial increase of approximately 158% over the past year. The company's market capitalization now stands at $1.24 billion, driven by strong investor confidence and recent positive developments. These include favorable …

Oculis rebuilds pipeline with Privosegtor buy from Accure

Oculis Holding AG has acquired all worldwide development and commercial rights to Privosegtor and ACT-02 from Accure Therapeutics for $3.8 million cash and up to 2,050,000 Oculis shares. This acquisition follows Oculis's Phase III OCS-01 failure and aims to consolidate its pipeline around these …

LeMaitre Vascular, Inc. (LMAT) Stock Analysis: Navigating a 39% Potential Upside in the Healthcare Sector

LeMaitre Vascular, Inc. (LMAT), a healthcare sector player specializing in vascular surgery medical devices, shows a potential upside of 39.33% with an average target price of $113.13. Despite trading below its 50-day and 200-day moving averages, the company exhibits strong operational efficiency, a healthy …

Royal Bank of Canada Trims Stock Position in Hercules Capital, Inc. $HTGC

Janus Henderson Group PLC Has $581,000 Holdings in Ocular Therapeutix, Inc. $OCUL

Janus Henderson Group PLC significantly reduced its stake in Ocular Therapeutix by 98.4% in the first quarter, now holding 68,500 shares valued at $581,000. Despite this, institutional investors collectively own 59.21% of the company. Ocular Therapeutix reported better-than-expected Q1 earnings, with a loss of …

AirSculpt Technologies (AIRS) Reaffirmed Guidance, Is The Sell Off Hiding Value?

Australian Agricultural Company (ASX:AAC) Share Price in Focus for Investors

IMDX Looks 284.7% Overvalued on GF Value™

Insight Molecular Diagnostics Inc (IMDX) is considered 284.7% overvalued based on its GF Value™ despite optimism around future FDA authorization for its GraftAssureDx test and expanded Medicare reimbursement. The company reported a Q2 adjusted EBITDA loss and an upward revision of its cash burn …

Agriculture & Natural Solutions Acquisition Corp Releases Q2 2024 10-Q Report

Agriculture & Natural Solutions Acquisition Corporation (ANSC) has released its Q2 2024 10-Q report, detailing financial performance including net income of $2.24 million for the quarter. The blank check company, formed to focus on decarbonizing agriculture and enhancing natural capital, completed its IPO in …

Oculis Announces Asset Purchase Agreement With Accure Therapeutics, Posts Q2 2026 Financial Results

Oculis Holding AG has announced an asset purchase agreement with Accure Therapeutics to acquire global rights to Privosegtor, a neuroprotective drug candidate, for an upfront payment of $3.8 million and up to 2,050,000 Oculis ordinary shares. This strategic move follows the failure of Oculis's …

Insight Molecular Diagnostics signals ~$8M quarterly cash burn in H2 2026 while targeting FDA authorization later this year

Earnings Call Insights: Insight Molecular Diagnostics (IMDX) Q2 2026 MANAGEMENT VIEW * "It feels great to be coming to you today with line of sight on expected FDA marketing authorization for GraftAssureDx" (President, CEO & Director Joshua Riggs), adding, "We continue to target receipt …

Australian Agricultural Company (ASX:AAC) Posts Record Operating Profit As Asset Gap Persists

Tabuk Agricultural Development's H1 Attributable Loss Narrows; Revenue Falls

Thrivent Financial (AIRS) discloses 4.4M-share beneficial stake in Airsculpt

Thrivent Financial and its affiliate Thrivent Investment Capital Advisors, LLC (TICA) have disclosed a beneficial ownership of 4,425,000 shares, or 6.3% of the class, in Airsculpt Technologies, Inc. This stake is held through Thrivent White Rose Fund XI Equity Direct, L.P. The filing, an …

Culpeo Minerals Director Increases Indirect Holdings via Entitlement Issue